Evonik Industries

SCENESSE, a new drug developed by the Australian company Clinuvel, used for treating erythropoietic protoporphyria (EPP) - a rare photosensitivity disorder, has now been granted regulatory approval from the European Medicines Agency (EMA). Read more


Evonik has expanded its technical service laboratory for pharmaceutical polymers in Shanghai from 130 to 750 m2 in response to Chinese pharmaceutical market growth. “The expansion was based on our excellent reputation in the region as a provider... Read more


Colorcon and Evonik Industries have signed a cooperation agreement for the marketing and technical support of Acryl-EZE, an aqueous acrylic enteric system. Read more


In March 2013, the Evonik Birmingham Laboratories site received cGMP certification from the MHRA. The MHRA, a competent UK authority, conducted the audit on behalf of the EMA in the course of registering a new product called SCENESSE for the... Read more